News about 'r&d'

Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Pando RH, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through Efflux. Am J Respir Crit Care Med. 2011 Apr 21. [Epub ahead of...

MIchael D. Iseman Dr. Michael D. Iseman, a world renowned pulmonologist and leading expert on tuberculosis has joined Oxford Immunotec as the Senior Scientific Advisor. To read full story, click here . In May 2010, the WGND had the honor of interviewing Dr. Iseman in our “Voices from the Fight to...

The MTBVAC01 vaccine candidate, developed to protect people against tuberculosis, will start Phase I clinical trials early in 2012. This was announced by the Spanish biopharmaceutical company Biofabri . The candidate was developed by the University of Zaragoza , Spain and is part of the...

Henao-Tamayo M, Irwin SM, Shang S, Ordway D, Orme IM. T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis. Tuberculosis (Edinb). 2011 Apr 27. [Epub ahead of print] In this week’s article, potential cellular biomarkers are explored in...

Dr. Edward Nardell, Partners in Health Summary: This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis; trained in pulmonary medicine at Massachusetts General Hospital with additional research training at Boston University School of...

Dr. Bernard Fourie Summary: The WGND had the opportunity to interview Dr. Bernard Fourie who is head of Medicine in Need-South Africa (MEND-SA). In addition, Dr. Fourie is an Extraordinary Professor of Medical Microbiology at the University of Pretoria, South Africa. In the interview, we discuss...

Dr. Peter Andersen, the Vice President of Vaccine Research and Development at Statens Serum Institut (SSI) and TBVI partner, has been awarded the prestigious Novo Nordisk prize for his work in TB vaccine development. The WGND interviewed Dr. Andersen for our TB R&D Weekly Update on March 8...

Photos of Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma Summary: The WGND had the opportunity to interview three researchers (Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma) involved in the groundbreaking research on the role of efflux pumps in contributing to drug tolerance...

Paul Elkington, Takayuki Shiomi, Ronan Breen, Robert K. Nuttall, Cesar Augusto Ugarte-Gil, Naomi F. Walker, Luísa Saraiva, Bernadette Pedersen, Francesco Mauri, Marc Lipman, Dylan R. Edwards, Brian D. Robertson, Jeanine D’Armiento and Jon S. Friedland. MMP-1 drives immunopathology in human...

The New York Academy of Sciences will be hosting a symposium entitled “New Frontiers in Marine Drug Discovery” on May 20, 2011. This 1-day symposium will overview the current state of the art in Marine Biomedicine and its role in the context of the drug discovery process – from the perspectives of...

Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC) , announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will...

Chen TC, Lu PL, Lin CY, Lin WR, Chen YH. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011 Mar;15(3):e211-6. Epub 2010 Dec 30. Chen, et al., conducted a meta-analysis to ascertain the answer to two...

Summary: Dr. Eric Nuermberger is Associate Professor of Medicine in the Division of Infectious Diseases, Department of Medicine, at Johns Hopkins University School of Medicine. The WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled “PA-824 exhibits time-dependent...

Global Health Primer by Disease This week BIO Ventures for Global Health launched a new online tool called the “Global Health Primer” which aims to be a clearinghouse of information geared to the biotech industry to encourage investments in neglected disease product development. The Primer...

[wpaudio url=”/blog/media/podcasts/Andersen_Peter_finished.mp3″ text=”Click here to play the Peter Anderson Podcast” dl=”0″] Summary: Dr. Peter Andersen is Vice President of Vaccine Research and Development at Statens Serum Institut (SSI). The WGND had the opportunity to talk with Dr. Andersen on a...